Medical Device | April 29, 2026
FDA okays AstraZeneca’s triple therapy Breztri for asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Aims to boost speed & precision in patient care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
